The Food and Drug Administration has authorized the commercial use of the norelgestromin and ethinyl estradiol transdermal system, known commercially as Gwyn Lo. This medication targets women specifically with a body mass index of less than 30 kg/m², marking a specific guideline for safe usage.
Regulatory approval was secured through the 505(b)(2) pathway, a route often utilized for generic or modified versions of previously authorized pharmaceuticals. Dr. Jeffrey Jensen, a professor of obstetrics and gynecology at Oregon Health & Science University, conducted an extensive review of the data from the phase 3 Luminous Study. He expressed confidence that the reported Pearl Index should not be viewed as a warning signal for clinicians.
Related: User Account Blocked by System Administrators
What the Pearl Index Means
The study results presented a Pearl Index of 4.14, a figure that falls within the 95% confidence interval of 2.77 to 5.95. The Pearl Index functions as the standard for measuring contraceptive failure rates within the medical community.
Jensen explained that the figure reflects an estimated pregnancy rate of approximately four women out of one hundred annually when the product is used correctly. The way it is calculated is the number of pregnancies that occur in the study divided by the number of evaluable at-risk cycles, he said, noting that the denominator “has really changed the Pearl Index over the years,” since cycles may be excluded for various reasons while pregnancies never are, he noted.
Efficacy of Non-Daily Methods
Non-daily administration does not inherently lower pregnancy rates, according to Jensen. The doctor noted that the same principle applies to vaginal rings as it does to the newly approved patch.
Related: User Account Blocked by Social Media Platform
If a patient uses the method correctly and consistently, the pregnancy rate remains comparable to that of daily oral combined pills. Jensen emphasized that patch-related problems are few and typically occur early in use.
He stated that the bottom line for clinicians should be helping patients find a method they can be most successful with. If a woman struggles with a pill regimen, a patch might offer a better solution.
